ARTEMIDE-Lung02: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Ril-vegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squa-mous Non-small Cell Lung Cancer Whose Tu-mors Express PD-L1

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express pro-grammed death-ligand 1 (PD-L1).